The increasing attention on MET exon 14 skipping is derived from the approval of two novel tyrosine kinase inhibitors (TKIs), namely capmatinib and tepotinib, for advanced stage NSCLC patients harboring this type of genomic alteration [12,13]. Here, MET is linked to non-small cell lung carcinoma.